Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

Diabetes Care

Volumn 22, Issue 3, 1999, Pages 468-477

  Lalli, Carlo ^a   Ciofetta, Marco ^a   Del Sindaco, Paola ^a   Torlone, Elisabetta ^a   Pampanelli, Simone ^a   Compagnucci, Pietro ^b   Cartechini, Maria Giulia ^b   Bartocci, Linda ^a   Brunetti, Paolo ^a   Bolli, Geremia B ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Ospedale di Camerino (AV3)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032972796     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.3.468     Document Type: Article

References (42)

1. Shade S, Santiago JV, Skyler JS, Rizza RA (Eds): Intensive Insulin Therapy. Amsterdam, Excerpta Medica, 1983
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)] human insulin, a rapidly absorbed analogue of human insulin. Diabetes, 43:396-402, 1994
4. Bolli GB: Rapid-acting insulin analogs. Curr Opin Endocrinol Diabetes 4:277-281, 1997
5. Anderson JH, Brunelle R, Koivisto VA, Pfützner A, Trautman ME, Vignati L, Di Marchi R: Insulin analogue treatment reduces postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients. Diabetes 46:265-270, 1997
6. Brunelle RL, Lilewelyn J, Anderson VA, Gale EAM, Koivisto VA: Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21:1726-1731, 1998
7. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH: Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 20:1827-1832, 1997
8. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack TR: Insulin Lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
9. lc. and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21:977-982, 1998
10. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, Brunetti P, Bolli GB: Use of the short-acting insulin analog lispro in intensive treatment of IDDM: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 15:592-600, 1998
11. Jansson P-A, Ebeling P, Smith U, Conget I, Coves MJ, Gomis R, Lalli C, Del Sindaco P, Bolli GB, Koivisto VA: Improved glycemic control can be better maintained with insulin lispro than with human regular insulin. Diabet Nutr Metab 11: 194-199, 1998
12. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA: Strategies towards improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care 20:1287-1289, 1997
13. Bolli GB: Hypoglycaemia unawareness. Diabete Metab 23 (Suppl. 3):29-35, 1997
14. lc, risk for severe and mild hypoglycaemia, status of counterregulation and unawareness of hypoglycaemia. Diabetologia 39:677-686, 1996
15. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. BMJ 285:916-918, 1982
16. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli GB: Effect of the short-acting insulin analog [LYS(B28),PRO(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
17. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, Durrant J, Cryer P, Gerich J: Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260:E67-E74, 1991
18. Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Ciofetta M, Modarelli F, Di Vincenzo A, Annibale B, Lepore M, Lalli C, Del Sindaco P, Brunetti P, Bolli GB: Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in, hypoglycaemia in humans. Diobetologia 37:797-807, 1994
19. De Feo P, Perriello G, Ventura MM, Calcinaro F, Basta G, Lolli C, Cruciani C, Dell'Olio A, Santeusanio F, Brunetti P, Bolli GB: Study on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: relevance to the pathogenesis of the dawn phenomenon. Diabetologia 29:475-480, 1986
20. McGuire E, Helderman J, Tobin R, Anders R, Bermnan M: Effects of artenal versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41:565-573, 1976
21. Schwartz N, Clutter W, Shah S, Cryer P: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. J Clin Invest 79:777-781, 1987
22. Fanelli C, De Feo P, Porcellati F, Perriello G, Torlone E, Santeusanio F, Brunetti P, Bolli GB: Adrenergic mechanisms contnbute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. J Clin Invest 89:2005-2013, 1992
23. Perriello G, Torlone E, Di Santo S, Fanelli C, De Feo P, Santeusanio F, Brunetti P, Bolli GB: Effects of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with IDDM. Diabetologia 31:811-815, 1988
24. Zar J: Biostatistical Analysis. Englewood Cliffs, NJ, Prentice Hall, 1984
25. Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI, Parving H-H: Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592-598, 1995
26. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, Chase HP: Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 13:47-52, 1996
27. Pfützner A, Küstner E, Forst T, Schulze-Schleppinghoff B, Trautman M, Haslbeck M, Schatz H, Beyer J: Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104:25-30, 1996
28. Rowe R, Anderson JH, Gale E: A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen. Diabetes 45 (Suppl. 2): 71A, 1996
29. Jacobs MAJM, Keulen ETP, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine RJ: Metabolic efficacy of preprandial administration of Lys(B28),Pro(B29) human insulin analog in IDDM patients. Diabetes Care 20:1279-1286, 1997
30. Ahmed ABE, Home PD: The effect of insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care 21:32-37, 1998
31. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycaemic control with insulin aspart. Diabetes Care 21:1904-1909, 1998
32. Ahmed ABE, Home PD: Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Diabetes Care 21:1707-1713, 1998
33. Torlone E, Del Sindaco P, Lalli C, Ciofetta M, Brunetti P, Bolli GB: Effect of lispro vs human regular insulin on long-term blood glucose control in IDDM: importance of time-interval between insulin injection and meal. Diabetes 47 (Suppl. 1):A101, 1998
34. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J: Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes 42:1233-1237, 1993
35. Kanc K, Janssen MMJ, Keulen ETP, Jacobs MAJM, Popp-Snijders C, Snoek, Heine RJ: Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM. Diabetologia 41:322-329, 1998
36. Antiserov M, Woodworth JR, Mayrov A, Ristic S, Dedov I: Within patient variability in postprandial glucose excursions with lispro insulin analog compared with regular insulin (Abstract). Diabetologia 38 (Suppl. 1):A190, 1995
37. Fanelli C, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini P, Porcellati F, Scionti L, Santeusanio F, Brunetti P, Bolli GB: Meticulous prevention of hypoglycemia (near-)normalizes magnitude and glycemic thresholds of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with IDDM of short duration. Diabetes 42:1683-1689, 1993
38. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA: Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 344: 283-287, 1994
39. Dagogo-Jack S, Rattarasarn C, Cryer PE: Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 43:1426-1434, 1994
40. Tsui EYL, Chiasson L-L, Tildesley H, Barnie A, Simkins S, Strack T, Zinman B: Counter-regulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin. Diabetes Care 21:93-96, 1998
41. Heller SR, Amiel SA, Macdonald IA, Tattersall RB: Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy (Abstract)? Diabetologia (Suppl. 1):A241, 1998
42. Janssen MMJ, Masurel M, Hoogma RPLM, Seubert M, Devillé W, Popp-Snijders C, Heine R: Effects of multiple injection therapy with lispro high mix insulin on the catecholamine response to hypoglycaemia (Abstract). Diabetologia 41 (Suppl. 1):A244, 1998